XARELTO®: Clinical trial and real-world evidence in stroke risk reduction in patients with nonvalvular atrial fibrillation (NVAF)
Extensive evidence of stroke risk reduction in patients with NVAF1-3
ROCKET AF Post Hoc Obesity Analysis2
NVAF and Morbid Obesity Real-World Study3
AF = atrial fibrillation; BMI = body mass index; CrCl = creatinine clearance; INR = international normalized ratio; N/A = not applicable; NVAF = nonvalvular atrial fibrillation; SE = systemic embolism; VTE = venous thromboembolism.